Our study revealed that PRMT5 and LSD1 are synchronously expressed in breast cancer patients and synergistic inhibition of PRMT5 and LSD1 significantly slows down the breast tumor growth and metastasis, providing a novel promising therapeutic strategy for patients with metastatic breast cancer. Here, KDM1A is linked to breast cancer.